Amyotrophic Lateral Sclerosis (ALS) remains a devastating neurodegenerative disease, demanding innovative therapeutic strategies. To better understand the evolving landscape of ALS drug development, I conducted an in-depth analysis of 7,219 patents, with a focus on the 5,160 patents published since 2010. This research provides a comprehensive overview of key therapeutic targets and modalities being explored.

𝘒𝘦𝘺 𝘧𝘪𝘯𝘥𝘪𝘯𝘨𝘴 𝘪𝘯𝘤𝘭𝘶𝘥𝘦:
- Identification of over 40 unique therapeutic targets.
- Mapping of diverse therapeutic modalities, including small molecules, ASOs, RNAi, Fabs, proteins, and cell/gene therapies.